News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cobra Biologics Ltd. and KAHR Medical Extend their Partnership to Develop Both KAHR-101 and KAHR-102



6/26/2012 9:12:52 AM

26 June 2012: Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals and KAHR Medical Limited, that develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases, announced today a continuation of their partnership.

The partnership will allow Cobra Biologics to advance both KAHR-101 and KAHR -102 for future pre-clinical and clinical testing using Cobra Biologic's maxXpress service which combines the UCOE protein expression technology with the experience and expertise of Cobra Biologics' cell line development team, to enable rapid clone selection and production. Cobra Biologics will also be carrying out the process development and scale up for the GMP production of both KAHR-101 and KAHR-102.

Peter Coleman, CEO at Cobra Biologics, said: "I am delighted to extend our partnership with KAHR which has been strengthened over a number of years due to the excellent working relationship between both technical teams and we look forward to its continuation."

Dr Noam Shani, CEO of KAHR Medical, said: "It has been a pleasure working with Cobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of both KAHR-101 and KAHR-102."

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com .

About Cobra Biologics: Cobra Biologics is a leading international clinical and commercial manufacturer of biologics and pharmaceuticals with three GMP approved facilities. We offer a broad range of integrated and stand-alone development services, stretching from cell line development through to the commercial supply of investigational medicinal product. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop drugs for the benefit of patients. Cobra Biologics provides manufacturing solutions to the biologics and pharmaceutical industry covering antibodies, recombinant proteins, viruses, DNA, cellular therapeutics and small molecules. www.cobrabio.com

About KAHR Medical: KAHR develops novel drugs that are based on the SCP (Signal Converter Proteins) platform technology for the treatment of cancer and autoimmune diseases. The SCP technology allows the construction of protein-based drugs with two functional sides. In contrast to current biological drugs that possess only one functional side, the two functional sides of SCPs allow these drugs to block or activate two reinforcing biological signals at the same time. The SCP platform forms a new generation of biological drugs with great diversity and superior efficacy. KAHR Medical is managed by Dr. Noam Shani.

www.kahr-medical.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44

(0) 207 861 3019 or e-mail: t.jervis@defacto.com


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES